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ganisms was then counted. The logarithmic reduction factor 
was calculated from the difference between the initial inoc-
ulum and the number of recovered test organisms.  Results: 
The disc carrier test allowed determination of an antimicro-
bial efficacy in a realistic setting. It also imposed more strin-
gent requirements on efficacy over time than the quantitative 
suspension test. The silver foam wound dressing showed a 
time-dependent antimicrobial efficacy. After 24-hour appli-
cation time, the reduction factors against  S. aureus ,  P. aerugi-
nosa and the methicillin-resistant  S. aureus were 1.9  8 0.15, 2.1 
 8 0.14 and 3.1  8 0.18, respectively.  Conclusion: The disc car-
rier test was a useful method for testing the antimicrobial ef-
ficacy of a foam silver dressing. The antimicrobial dressing
exhibited an antimicrobial effect after 3 h and achieved a re-
duction  1 2 log against the tested bacterial strains in the pres-
ence of a simulated wound secretion after 24 h.
 Copyright © 2011 S. Karger AG, Basel
 Introduction
 At present, there is no universally recognized test hi-
erarchy for assessing the antimicrobial efficacy of wound 
antiseptics and antimicrobial wound dressings. The an-
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 Abstract
 Aim: The efficacy of antimicrobial compounds included in 
wound dressings has been determined using the quantitative 
suspension test according to EN 13727 before. However, as 
suspension tests are not an accurate reflection of the condi-
tions under which wound antiseptics are used, it was investi-
gated if a disc carrier test would yield results simulating prac-
tical conditions on wound surfaces. A silver-leaching foam 
wound dressing was used for evaluation of the disc carrier test 
method.  Method: The disc carriers consisted of circular stain-
less-steel discs measuring 2 cm in diameter and 1.5 mm in 
thickness, complying with the requirements of EN 10088-2. 
Carriers were contaminated with  Staphylococcus aureus , 
methicillin-resistant  S. aureus or  Pseudomonas aeruginosa , re-
spectively, together with an artificial wound secretion and left 
to dry at room temperature for 30 min. The wound dressings 
being tested were placed on the discs for the length of the 
exposure time, and after neutralization by thioglycolate in 
phosphate-buffered saline the number of surviving test or-
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timicrobial efficacy of wound antiseptics is generally in-
vestigated in a quantitative suspension test with and 
without biotope-adjusted challenge  [1] according to EN 
13727. In order to achieve plausible and correct results, it 
is paramount that a suitable neutralization medium is se-
lected in order to avoid distortion of the results as a con-
sequence of active substance traces entering the nutrient 
medium; if the neutralization process is not completely 
effective, the active substance traces in the test set-up will 
continue to be antimicrobially active resulting in a wrong 
impression that the active substance is more effective at a 
certain contact time than it really is. Currently, for wound 
antiseptics tested in a suspension test it is required to 
achieve a  6 5 log reduction with no organic challenge and 
a  6 3 log reduction in the presence of a biotope-typical 
organic challenge  [1] .
 Because a quantitative suspension test cannot repro-
duce the conditions under which wound antisepsis is per-
formed in clinical practice, we investigated first whether a 
carrier test was suitable for testing the antimicrobial effi-
cacy as a phase 2, step 1 test under practice-relevant condi-
tions. The model presented here is a closer reflection of the 
circumstances under which wound antiseptics are used 
because in contrast to a quantitative suspension test in 
which the antiseptic is mixed with the test micro-organ-
isms placed in the suspension and the number of test or-
ganisms killed in samples of the suspension is compared 
with the number of test organisms in the control solution, 
in the carrier test the micro-organisms are placed on a 
disc, dried and only then covered with the wound antisep-
tic in the form of a liquid, ointment or wound dressing. 
The number of surviving test micro-organisms is counted 
once the exposure time has elapsed. This test model will 
also allow investigators to ascertain the impact on the ef-
ficacy of a challenge comparable to wound secretion.
 As the efficacy of wound dressings containing silver is 
the subject of intense debate in the literature  [2] , and sus-
pension tests of mild silver protein, silver sulphadiazine 
and silver nitrate have shown these substances to be prac-
tically ineffective when presented with a protein challenge 
in suspension  [3] , we aimed to compare the antimicrobial 
efficacy of a wound dressing containing silver with that of 
a wound dressing containing no silver in a carrier test.
 Method
 Study Substances
 The study was conducted using Biatain Ag (Coloplast GmbH, 
Hamburg, Germany), a foam dressing containing homogeneous-
ly distributed silver, which continuously releases silver for up to 7 
days when in contact with wound exudate. The identical foam 
dressing without silver (Biatain, Coloplast GmbH) served as con-
trol for the purpose of this study.
 Pathogens
 The test organisms used were  Staphylococcus aureus ATCC 
6538, methicillin-resistant  Staphylococcus aureus  North German 
epidemic strain and  Pseudomonas aeruginosa ATCC 15442.
 Challenge
 The substance used as challenge, simulating wound fluid  [3] , 
was Eagle’s minimal essential medium with Earle’s salts and  L -
glutamine (PAA Laboratories, Germany), to which 10% fetal bo-
vine serum (Gibco, Life Technologies GmbH, Darmstadt, Ger-
many) was added.
 Discs
 The carrier discs used were circular stainless-steel discs, 2 cm 
in diameter and 1.5 mm thick (1.4301, surface grade 2B), comply-
ing with the requirements of EN 10088-2.
 Neutralization
 Before the carrier test was conducted, the appropriateness of 
possible neutralization media was evaluated in a pre-analytic test. 
The most suitable neutralized for the silver dressing was found to 
be 0.1% thioglycolate in phosphate-buffered saline. This com-
pound was therefore used in the further carrier test.
 Test Suspension
 Test strains were cultured in an overnight culture on blood 
agar and incubated for 24 h at 36  8 1   °   C. A colony was taken from 
each of the test strains, placed on blood agar once again and in-
cubated again for 24 h at 36  8 1   °   C. The resulting subcultures 
were prepared and used as working cultures. Prior to the start of 
the test, the suspensions were made by diluting 1 ml of the test 
strain solution in 9 ml of tryptone-NaCl. 
 Multiple dilution steps in tryptone-NaCl were performed in 
order to ensure that the tests could be conducted with sufficient-
ly high test strain counts (approx. 10 8 –10 9  CFU/ml). 0.1 ml of each 
of the 10 –6 , 10 –7  and 10 –8  dilutions were transferred by a sterile 
spatula onto agar plates using the double method and incubated 
for 48 h at 36  8 1   °   C. Colony counts were then performed to check 
the microbial density. The efficacy of the wound dressings was 
assessed by comparison with the final test strain counts of con-
taminated disc carriers which were left to dry but not covered 
with wound dressings serving as positive controls.
 Performance and Assessment of the Test
 The metal discs were placed in sterile Petri dishes. 0.05 ml of 
the test strain suspension in the challenge medium was placed on 
the surface, and a sterile glass spatula was used to gently spread 
the suspension in a circular direction. Care was taken to leave a 
1- to 2-mm gap between the solution and the outer edge of the disc 
in order to ensure that the wound dressings completely covered 
the wetted surface ( fig. 1 ).
 The sterile samples cut to match the wound dressing were then 
placed in sterile Petri dishes into which challenge fluid had previ-
ously been transferred by pipette. They were left in place for 1 min 
to allow the samples to be completely wetted with the solution and 
to become saturated with it (the samples were turned in the solu-
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tion after 30 s). The samples were then placed on the contami-
nated test carriers, with care being taken to ensure that the test 
carriers were completely covered by the wound dressings and that 
no gaps were left. In order to assure that contact with the con-
taminated disc test carrier surface was maintained, a second disc 
test carrier (mass 3.8 g) was placed on top of each sample for the 
duration of the exposure time ( fig. 2 ).
 After the exposure times had elapsed (5, 30 min, 3, 10 and
24 h), the disc test carriers were transferred to sterile examination 
tubes (Greiner Bio-One GmbH, Solingen, Germany) that had pre-
viously been filled with sterile glass beads and 10 ml of neutral-
izing agent. The metal disc test carriers were positioned with the 
contaminated surfaces facing downwards. They were able to 
move freely on the glass beads in the horizontal plane. The tubes 
were agitated on a vortexer for 2 min to dissolve the pathogens. 
After a neutralization time of 5–30 min, 1 ml of the test-neutral-
izer mixture was removed and placed in 9 ml of tryptone-NaCl. 
0.1 ml of this mixture and subsequent dilutions were spread on 
sets of 2 Petri dishes. The colonies were counted after 48 h of in-
cubation at 36  8 1   °   C.
 Only agar plates with colony counts ranging from 15 to 300 
CFU were taken into account when evaluating the tests. The 
weighted averages of the consecutive dilutions were calculated as 
follows:
 
 l
1 20 1
cC (n . n )d 
 where  Ĉ = weighted average;  c = sum of the colonies on all nutri-
ent media assessed;  n 1  = number of nutrient media assessed with 
the first dilution;  n 2  = number of nutrient media assessed with the 
second dilution;  d = dilution factor of the first dilution assessed.
 Results
 The antimicrobial effect on both  Staphylococcus 
strains started after 3 h at the earliest (significant log re-
duction compared to the positive control at the p = 0.05 
significance level), while a similar effect on  P. aerugi-
nosa could be observed after already 30 min (p  ! 0.05, 
 table 1 ). The antimicrobial effect increased with time, 
and the reduction factors after 24 h against  S. aureus ,  P. 
aeruginosa and the methicillin-resistant  S. aureus strain 
were 1.9  8 0.15, 2.1  8 0.14 and 3.1  8 0.18, respectively 
( table 1 ).
 Biatain without silver which served as negative control 
did not show any antimicrobial efficacy, as expected. In 
contrast, the non-antimicrobial wound dressing even 
showed an increase of  1 1 log in the number of test bacte-
ria after 24 h (for  P. aeruginosa almost even after 10 h). 
After 24 h, methicillin-resistant  S. aureus ,  S. aureus and 
 P. aeruginosa showed an increase of 1.1  8 0.23, 1.7  8 0.16 
and 1.8  8 0.17 log. This increase was most likely due to 
the moisture on the slide and almost reached 2 log in the 
case of  P. aeruginosa ( table 1 ).
 Discussion
 We found the disc carrier test to be a useful and easy-
to-apply method to assess the antimicrobial efficacy of
an antimicrobial wound dressing. Furthermore, the test 
method allows a more realistic assessment simulating 
conditions on the wound surface. It also imposes more 
stringent requirements on antimicrobial efficacy over 
time than a quantitative suspension test, since contact be-
tween the wound dressing and the test organism suspen-
sion to which the dressing is exposed is less intense than 
during a suspension test where the dressing is placed in a 
test solution containing test organisms at planktonic and 
dynamic conditions.
 So far, it is accepted that if an antimicrobial compound 
fulfils the requirements for quantitative suspension tests, 
the next step will involve testing against an established 
 Fig. 1. Dried pathogen suspension on a metal disc carrier.
 
 Fig. 2. Test carrier with a wound dressing covered by an uncon-
taminated test carrier. 
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reference standard in healthy volunteers  [4] ; yet, this is 
not possible for wound antiseptics, as no models for an 
infected wound in healthy subjects exist  [5] . Therefore, 
the only possibility is to test the antimicrobial efficacy on 
mesh graft donor sites in patients, when such a procedure 
is clinically indicated  [6] . However, this test will allow 
only conclusions on antimicrobial efficacy against physi-
ological colonization flora on the wound surface, since 
controlled contamination with pathogens is unethical. 
The only true possibility of testing antimicrobial efficacy 
and the clinical benefit is therefore to conduct a clinical 
randomized controlled trial (RCT) on wounds that can 
be compared with each other, such as chronic infected 
crural ulcers. Because of the prohibitive costs of RCTs 
and the difficulties associated with coordination of mul-
ti-centre trials, before even considering RCTs, as much 
information as possible should be available on the anti-
microbial efficacy of the compounds to be tested. The in-
formation needed is more than what can be provided by 
suspension tests and must be derived from other tests, 
such as examination of efficacy in disc carrier tests (ini-
tially with no biofilm, and once the substance has been 
shown to be effective with a biofilm placed on the disc 
carrier prior to the test) as well as comprehensive in vitro 
and semi in vivo tolerance testing. 
 Quantitative suspension tests have found silver com-
pounds confronted with a protein challenge to be ineffec-
tive  [3] , but the silver wound dressing Biatain Ag tested 
here was found to have a significant bactericidal effect 
after 10–24 h and against  P. aeruginosa even after a 30-
min exposure time.
 However, the test results do not allow the conclusion 
that wound dressings containing silver also lead to the 
desired clinical effect of improved chronic wound heal-
ing because the in vitro nature of the disc carrier test will 
not examine the possible cytotoxic effect on wounds. It is 
always important to rule out the risk of wound healing 
being inhibited by silver ions  [7] in silver ion-leaching 
wound dressings releasing silver into the wound. In vitro 
tests have shown that the addition of ionic silver to algi-
nate improves antimicrobial efficacy and the ability to 
bond to elastase, matrix metalloproteinase-2 and pro-in-
flammatory cytokine, and increases anti-oxidative ca-
pacity; however, this is achieved on the backside of a sig-
nificant keratinocyte inhibition  [8] .
 A Cochrane analysis assessing the clinical efficacy of 
silver wound dressings found only 3 RCTs with a short 
follow-up. All tested silver wound dressings did not 
achieve any significant improvement in ulcer healing, al-
though the ulcers treated with a silver foam dressing did 
tend to decrease in size. The authors conclude that there 
is insufficient evidence for the use of wound dressings or 
topical antiseptics containing silver in the treatment of 
infected or contaminated wounds  [9] . In another meta-
analysis, 8 studies from 1,957 relevant sources were as-
sessed. The conclusion was that wound dressings con-
taining silver significantly improved the healing process 
of chronic, poorly healing wounds, with reduced wound 
odour, exudation and pain  [10] . However, a further meta-
analysis published in the same year found no clear evi-
dence in favour of recommending foam dressings or al-
ginate wound dressings containing silver for the treat-
ment of infected chronic wounds for a period of 4 weeks 
 [11] . Nevertheless, foam dressings containing silver did 
achieve a trend-wise greater reduction in wound area, ex-
udation and odour compared to wound dressings not 
containing silver. Because the silver dressing was antisep-
tically effective in our disc carrier model, we conclude 
 Table 1.  Efficacy of the silver wound dressing Biatain Ag compared to an identical wound dressing without silver (mean of 9 test runs 
with each run assessed twice, giving a total of 18 results)
 Exposure
 time 
 S. aureus
 (control 5.9 log) 
 MRSA
 (control 5.9 log) 
 P . aeruginosa
 (control 6.1 log) 
 Biatain Ag Biatain  Biatain Ag  Biatain  Biatain Ag Biatain 
5 min  0.3 8 0.14 0.1 8 0.08  0.7 8 0.25  0.5 8 0.18  0.2 8 0.12 0.1 8 0.12 
 30 min  0.3 8 0.1 0.1 8 0.1  0.7 8 0.19  0.3 8 0.27  1.1 8 0.15* 0.3 8 0.16 
3 h  1.3 8 0.1* 0.0 8 0.11  2.0 8 0.15*  0.6 8 0.26  1.2 8 0.17* 0.1 8 0.15 
 10 h  1.6 8 0.34* 0.1 8 0.09  2.2 8 0.23*  0.4 8 0.15  1.3 8 0.13*  –0.9 8 0.13 
 24 h  1.9 8 0.15*  –1.7 8 0.16  3.1 8 0.18*  1.1 8 0.23  2.1 8 0.14*  –1.8 8 0.17 
 MR SA = Methicillin-resistant  S. aureus. * p < 0.05: significant difference to control, assessed by t test. 
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that RCTs with a longer follow-up period are necessary in 
order to identify the most suitable wound dressing for the 
treatment of contaminated and infected acute and chron-
ic wounds  [11] .
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